You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMelphalan
Accession NumberDB01042  (APRD00118)
TypeSmall Molecule
GroupsApproved
DescriptionAn alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen. [PubChem]
Structure
Thumb
Synonyms
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysine
Melfalano
Melphalanum
p-Bis(beta-chloroethyl)aminophenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlkeranKitApopharma Inc2011-01-01Not applicableUs
AlkeranTablet2 mgOralAspen Pharma Trading Limited1964-12-31Not applicableCanada
AlkeranTablet, film coated2 mg/1OralApopharma Inc2011-01-01Not applicableUs
EvomelaInjection, powder, lyophilized, for solution50 mg/10mLIntravenousSpectrum Pharmaceuticals, Inc.2016-03-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Melphalan HydrochlorideKitGenera Medix Inc.2009-10-27Not applicableUs
Melphalan HydrochlorideKitIntravenousSagent Pharmaceuticals2016-09-092017-01-13Us
Melphalan HydrochlorideKitMylan Institutional2013-01-10Not applicableUs
Melphalan HydrochlorideInjection, powder, lyophilized, for solution50 mg/10mLIntravenousPar Pharmaceutical2016-08-26Not applicableUs
Melphalan HydrochlorideKitMylan Institutional2013-01-10Not applicableUs
Melphalan HydrochlorideKitIntravenousActavis Pharma Company2017-01-13Not applicableUs
Melphalan HydrochlorideKitMylan Institutional2014-09-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AlkeranAspen Pharma Trading Limited
Salts
Name/CASStructureProperties
Melphalan hydrochloride
3223-07-2
Thumb
  • InChI Key: OUUYBRCCFUEMLH-YDALLXLXSA-N
  • Monoisotopic Mass: 340.051211
  • Average Mass: 341.66
DBSALT001019
Categories
UNIIQ41OR9510P
CAS number148-82-3
WeightAverage: 305.2
Monoisotopic: 304.074533244
Chemical FormulaC13H18Cl2N2O2
InChI KeySGDBTWWWUNNDEQ-LBPRGKRZSA-N
InChI
InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
IUPAC Name
(2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid
SMILES
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Pharmacology
IndicationFor the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Structured Indications
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceMultiple Myeloma (MM)1
0RecruitingTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1Active Not RecruitingSupportive CareAcute Myeloid Leukemia in Remission / Primary Myelofibrosis / Primary Myelofibrosis, Prefibrotic Stage / Secondary Acute Myeloid Leukemia / Secondary Myelofibrosis1
1Active Not RecruitingTreatmentLeukemias / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentLymphoma NOS / Lymphoma, B-Cell1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1Active Not RecruitingTreatmentNeuroblastomas1
1Active Not RecruitingTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1CompletedSupportive CareMucositis / Multiple Myeloma (MM)1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplastic Syndrome1
1CompletedTreatmentAllogeneic Stem Cell Transplantation / Malignancies, Hematologic1
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Leukemias / Lymphoma NOS1
1CompletedTreatmentCancer, Ovarian2
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentCongenital Marrow Failures / Hemoglobinopathies / Immunodeficiencies / Inborn Errors of Metabolism / Lysosomal Storage Diseases / Non Malignant Disorders / Sickle Cell / Thalassemias1
1CompletedTreatmentEwings Sarcoma1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1CompletedTreatmentLiver Cancer / Metastatic Cancers1
1CompletedTreatmentLymphoma NOS4
1CompletedTreatmentMelanoma (Skin)1
1CompletedTreatmentMultiple Myeloma (MM)2
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Liver1
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Liver1
1CompletedTreatmentNeuroblastomas3
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentSarcomas1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentWiskott-Aldrich Syndrome (WAS)1
1Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / Adult Diffuse Large B-Cell Lymphoma / CD20-Positive Neoplastic Cells Present / Indolent Adult Non-Hodgkin Lymphoma / Mantle Cell Lymphoma (MCL) / Recurrent B-Cell Non-Hodgkin Lymphoma / Refractory Mature B-Cell Non-Hodgkin Lymphoma1
1Not Yet RecruitingTreatmentLeukemias1
1RecruitingNot AvailableDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingNot AvailableMultiple Myeloma (MM)1
1RecruitingBasic ScienceHematopoietic Stem Cell Transplantation (HSCT)1
1RecruitingTreatmentAplastic Anaemia (AA) / Chronic Leukemias / Congenital Hematological Disorder / Immune Deficiency Disorder / Leukaemia, Acute / Lymphoma NOS / Metabolism Disorder / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Tumors, Solid1
1RecruitingTreatmentBlood And Marrow Transplantation / Leukemias / Lymphoma NOS / Transplantation Infection / Transplantation, Bone Marrow1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1RecruitingTreatmentClear Cell Carcinoma / Gastrointestinal Tumors / Germ Cell Tumors / Hepatic Tumors / Lymphoma NOS / Melanoma / Neuroblastomas / Non-rhabdomyosarcoma / Renal Cell Carcinoma (RCC) / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Ewing's / Wilms Tumor1
1RecruitingTreatmentHematological Diseases / Immune Deficiencies / Lymphoma NOS / Multiple Myeloma (MM) / Myelofibrosis / Tumors, Solid1
1RecruitingTreatmentHigh-risk Tumor / Lymphoma NOS / Neuroblastomas1
1RecruitingTreatmentLeukemia, Plasma Cell / Recurrent Plasma Cell Myeloma1
1RecruitingTreatmentMature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentMultiple Myeloma (MM)3
1RecruitingTreatmentMultiple Myeloma, Refractory to Standard Treatment / Multiple Myeloma, Relapsed1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentPreviously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Hematologic Malignancy1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1RecruitingTreatmentSpinal Diseases / Spinal Metastases / Spinal Tumors1
1TerminatedSupportive CareBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Chordomas / Kidney Cancer / Liver Cancer / Neuroblastomas / Retinoblastoma / Sarcomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Kidney Cancer / Liver Cancer / Retinoblastoma / Sarcomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Metastatic Cancers1
1TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1TerminatedTreatmentDrug/Agent Toxicity by Tissue/Organ / Multiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentGraft Versus Host Disease (GVHD) / Lymphoma NOS / Myelodysplastic Syndrome / Myelomas / Myeloproliferative Disorders1
1WithdrawnTreatmentLeukemias / Lymphoma NOS1
1WithdrawnTreatmentLeukemias / Lymphoma NOS / Pediatric Disorders / Transplantation, Stem Cell1
1WithdrawnTreatmentMelanoma (Skin)1
1WithdrawnTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1WithdrawnTreatmentSarcoma, Ewing's1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Lymphoma NOS1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAdvanced Hematologic Malignancies / Leukemias / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Leukemias / Lymphoma NOS / Neuroblastomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentInfection NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1, 2CompletedTreatmentLeukemias / Lymphoma NOS / Myelomas1
1, 2CompletedTreatmentLymphoma NOS1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)4
1, 2CompletedTreatmentMultiple Myeloma (MM) / Patient Participation1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Transplantation, Stem Cell1
1, 2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
1, 2CompletedTreatmentMyelomas2
1, 2CompletedTreatmentMyelomas / Transplantation, Stem Cell1
1, 2CompletedTreatmentNeoplasms1
1, 2Not Yet RecruitingTreatmentFollicular Lymphoma (FL) / Hodgkin's Lymphoma - Relapsed/Refractory / Non-Hodgkin's Lymphoma - Aggressive1
1, 2Not Yet RecruitingTreatmentLymphoma NOS2
1, 2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1, 2RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Mixed Glioma / Adult Oligodendroglioma / Oligoastrocytoma / Recurrent Adult Brain Neoplasm1
1, 2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentBeta Thalassemia-Major / Sickle Cells Disease1
1, 2RecruitingTreatmentCentral Nervous System Embryonal Tumor / Germ Cell Tumors1
1, 2RecruitingTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic / Relapses1
1, 2RecruitingTreatmentHematologic, Immune, or Bone Marrow Disorders / Hemoglobinopathies / Metabolic Disorders / Non-malignant Disorders1
1, 2RecruitingTreatmentLeukemias / Myelomas / Myeloproliferative Diseases1
1, 2RecruitingTreatmentLeukemias / Myeloproliferative Diseases1
1, 2RecruitingTreatmentMultiple Myeloma (MM)3
1, 2RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2RecruitingTreatmentMultiple Myeloma in Relapse1
1, 2RecruitingTreatmentMyelomas1
1, 2SuspendedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2TerminatedTreatmentAnemias / Immunodeficiencies / Leukemias / Lymphoma NOS / Neuroblastomas1
1, 2TerminatedTreatmentCancers / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentChronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy / Leukaemia, Acute / Lymphoma, Hodgkins / Malignancies, Hematologic / Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes / Myelomas / Non-Hodgkin's Lymphoma (NHL)1
1, 2TerminatedTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentMyelomas1
1, 2TerminatedTreatmentPlasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2WithdrawnTreatmentMelanoma1
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
2Active Not RecruitingSupportive CareChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Paroxysmal Nocturnal Hemoglobinuria (PNH) / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Severe Combined Immunodeficiency / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myelogenous Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL) / Sarcoma, Myeloid1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Histiocytosis / Myelodysplasia1
2Active Not RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentBlood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic1
2Active Not RecruitingTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentDiffuse Large Cell Lymphoma / Lymphoma NOS1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS1
2Active Not RecruitingTreatmentHIV Disease / Leukemias / Lymphoma NOS1
2Active Not RecruitingTreatmentHemoglobinuria, Paroxysmal Nocturnal (PNH) / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia, Acute Lymphocytic (ALL) / Leukemia, Myeloid, Acute(AML) / Leukemia, Myeloid, Chronic(CML) / Lymphoma, Hodgkins / Lymphoma, Non-Hodgkin (NHL) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentJuvenile Myelomonocytic Leukemia1
2Active Not RecruitingTreatmentKidney Cancer1
2Active Not RecruitingTreatmentLeukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
2Active Not RecruitingTreatmentLymphoma NOS8
2Active Not RecruitingTreatmentLymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)7
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Neurotoxicity1
2Active Not RecruitingTreatmentMyelomas1
2Active Not RecruitingTreatmentNeuroblastomas2
2Active Not RecruitingTreatmentProstate Cancers1
2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentRefractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentSevere Thalassemia1
2CompletedNot AvailableMultiple Myeloma (MM)1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukemia, Lymphoid / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2CompletedTreatmentAdrenoleukodystrophy / Gangliosidosis, GM1 / I-Cell Disease / Leukodystrophy, Globoid Cell / Metachromatic Leukodystrophy / Sandhoffs Disease / Sanfilippo Syndrome / Tay Sachs Disease / Wolman's Disease1
2CompletedTreatmentAllogeneic Marrow Transplant / Leukemias / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAmyloidosis2
2CompletedTreatmentAngiogenesis / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2CompletedTreatmentBlood Cancers / Multiple Myeloma (MM)1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Breast / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentCancers1
2CompletedTreatmentColorectal Cancers / Islet Cell Tumor / Liver Cancer / Metastatic Cancers / Neuroendocrine Carcinomas1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers2
2CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Inflammatory carcinoma of the breast / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentEwings Sarcoma / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Neuroblastomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentHodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2CompletedTreatmentLeukemias3
2CompletedTreatmentLeukemias / Lymphoma NOS3
2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma (MM)1
2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLiver Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentLymphoma NOS11
2CompletedTreatmentLymphoma NOS / Multiple Myeloma (MM)1
2CompletedTreatmentLymphoma NOS / Transplantation, Bone Marrow1
2CompletedTreatmentLymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentLymphoma, Large Cell, Diffuse1
2CompletedTreatmentMantle Cell Lymphoma (MCL)1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMelanoma (Skin) / Sarcomas1
2CompletedTreatmentMultiple Myeloma (MM)8
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
2CompletedTreatmentMultiple Myeloma (MM) / Primary Amyloidosis1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm16
2CompletedTreatmentMyelomas1
2CompletedTreatmentNeuroblastomas3
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage IIB Adult Soft Tissue Sarcoma / Stage IIC Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IVA Adult Soft Tissue Sarcoma / Stage IVB Adult Soft Tissue Sarcoma1
2CompletedTreatmentRefractory Plasma Cell Neoplasm / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentSarcomas3
2CompletedTreatmentTumor, Brain / Tumors, Central Nervous System1
2Not Yet RecruitingTreatmentAmyloidosis; Systemic1
2Not Yet RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas1
2Not Yet RecruitingTreatmentLymphoma NOS3
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentNK/T Cell Lymphoma1
2Not Yet RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / CMML / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myelofibrosis / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Hematopoietic Stem Cell Transplant (HSCT) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia1
2RecruitingTreatmentAllogeneic Hematopoietic Stem Cell Transplantation / Neuroepithelial Tumor / Tumors, Solid1
2RecruitingTreatmentAplastic Anaemia (AA) / Multiple Myeloma (MM) / Myelofibrosis / Neoplasms, Hematologic / Paroxysmal Hemoglobinuria1
2RecruitingTreatmentAutoimmune Disorders1
2RecruitingTreatmentAutoimmune Lymphoproliferative Syndrome / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immune Deficiency (CVID) / DiGeorge's syndrome / Hyper-IgM / Immune Deficiency Disorders / Immune Dysregulatory Disorder / IPEX / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Wiskott-Aldrich Syndrome (WAS) / X-Linked Agammaglobulinemia / X-Linked Lymphoproliferative Syndrome1
2RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Leukemia, Plasma Cell / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentBeta Thalassemia / Bone Marrow Failure / Histiocytosis / Immunodeficiencies / Inborn Errors of Metabolism / Leukemias / Lymphoma NOS / Sickle Cells Disease1
2RecruitingTreatmentChildhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2RecruitingTreatmentCongenital Bone Marrow Failure Syndromes / Hereditary Anemias / Inherited Metabolic Disorders (IMD) / Patients With Sickle Disease Presenting Specific Symptoms / Primary Immunodeficiency Syndromes1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-cell Lymphoma (DLBCL)1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentHematological Malignancy1
2RecruitingTreatmentHepatocellular Carcinomas / Intrahepatic Cholangiocarcinoma1
2RecruitingTreatmentLeukemia, Erythroblastic, Acute / Myelodysplastic Syndromes1
2RecruitingTreatmentLeukemias / Lymphoma NOS1
2RecruitingTreatmentLeukemias / Lymphoma NOS / Myelomas / Myeloproliferative Diseases1
2RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
2RecruitingTreatmentLymphoma NOS / Small Intestine Cancer1
2RecruitingTreatmentMedulloblastomas / Neuroectodermal Tumors, Primitive / Tumor, Brain1
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentMultiple Myeloma (MM)11
2RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2RecruitingTreatmentMyelomas1
2RecruitingTreatmentNeuroblastomas2
2RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)2
2RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2RecruitingTreatmentProstate Cancers1
2RecruitingTreatmentRefractory and/or Relapsed Metastatic Solid Tumors1
2RecruitingTreatmentRetinoblastoma1
2RecruitingTreatmentSarcoma of Pelvis1
2RecruitingTreatmentSickle Cells Disease1
2RecruitingTreatmentSmoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma1
2RecruitingTreatmentTesticular Cancer1
2RecruitingTreatmentTumor, Brain1
2TerminatedDiagnosticLymphoma NOS1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCancer, Breast / Cancer, Ovarian1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia, Lymphoblastic, Acute / Leukemia, Myeloid, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Lymphoma NOS1
2TerminatedTreatmentHematological Diseases1
2TerminatedTreatmentHistiocytosis, Langerhans-Cell1
2TerminatedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2TerminatedTreatmentLeukemias / Lymphoma NOS / Myelomas / Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Lymphoma NOS / Other Haematological Diseases1
2TerminatedTreatmentLymphoma NOS1
2TerminatedTreatmentMultiple Myeloma (MM)4
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentMyelomas1
2TerminatedTreatmentRenal Cell Cancer1
2TerminatedTreatmentRetinoblastoma1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2WithdrawnPreventionMultiple Myeloma (MM)1
2WithdrawnTreatmentLymphoma NOS1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentMyelomas1
2WithdrawnTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentRefractory Plasma Cell Neoplasm / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2, 3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2, 3CompletedTreatmentLymphoma NOS1
2, 3RecruitingTreatmentCastrate Resistant Prostate Cancer (CRPC)1
2, 3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2, 3RecruitingTreatmentMultiple Myeloma (MM)1
2, 3TerminatedTreatmentAML / Leukemia, Lymphocytic, Acute / MDS1
2, 3TerminatedTreatmentNeuroblastomas1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
3Active Not RecruitingTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLymphoma NOS4
3Active Not RecruitingTreatmentMultiple Myeloma (MM)7
3Active Not RecruitingTreatmentMultiple Myeloma (MM) / Newly Diagnosed Patients1
3Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm5
3Active Not RecruitingTreatmentNeuroblastomas1
3Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
3Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentAcute Myeloid Leukaemias (AML)1
3CompletedTreatmentAmyloidosis1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentCancer, Ovarian1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentIntraocular Melanoma / Melanoma (Skin) / Metastatic Cancers1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentLymphoma NOS4
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentMelanoma1
3CompletedTreatmentMultiple Myeloma (MM)8
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
3CompletedTreatmentNeuroblastomas3
3CompletedTreatmentPrimary Systemic Amyloidosis (AL)1
3CompletedTreatmentRecurrent Melanoma / Stage III Melanoma1
3CompletedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3No Longer AvailableNot AvailableMultiple Myeloma (MM)1
3RecruitingTreatmentAL Amyloidosis2
3RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentLeukemias / Mucositis / Oral Complications1
3RecruitingTreatmentLymphoma NOS1
3RecruitingTreatmentLymphoma, Mantle-Cell1
3RecruitingTreatmentMultiple Myeloma (MM)4
3RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3RecruitingTreatmentMyelomas1
3RecruitingTreatmentNeuroblastomas3
3RecruitingTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSarcoma, Ewing's1
3RecruitingTreatmentSarcomas1
3TerminatedTreatmentLeukemia, Myelocytic, Acute1
3TerminatedTreatmentMultiple Myeloma (MM)2
3TerminatedTreatmentNewly Diagnosed, Multiple Myeloma1
4CompletedNot AvailableMultiple Myeloma (MM)1
Not AvailableActive Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Paroxysmal Nocturnal Hemoglobinuria (PNH) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Plasma Cell Neoplasms / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Neuroblastoma / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Regional Neuroblastoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Central Nervous System Germ Cell Tumor / Adult Rhabdomyosarcoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Soft Tissue Sarcoma / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Ovarian Mixed Germ Cell Tumor / Previously Untreated Childhood Rhabdomyosarcoma / Recurrent Adult Brain Tumor / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Extragonadal Germ Cell Tumor / Recurrent Extragonadal Non-seminomatous Germ Cell Tumor / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Neuroblastoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Sarcoma, Ewing's / Tumors, Solid / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableActive Not RecruitingTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableActive Not RecruitingTreatmentHodgkins Disease (HD) / Lymphoma NOS1
Not AvailableActive Not RecruitingTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentLymphoma NOS1
Not AvailableActive Not RecruitingTreatmentMyelomas1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplasia1
Not AvailableCompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentAcute Myeloid Leukaemias (AML) / Aplastic Anaemia (AA) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukaemia, Acute / Leukemia, Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Myelofibrosis / Myeloproliferative Disorders / Polycythemia Vera (PV)1
Not AvailableCompletedTreatmentAmyloidosis / Leukemias1
Not AvailableCompletedTreatmentHodgkins Disease (HD)1
Not AvailableCompletedTreatmentLymphoma NOS1
Not AvailableCompletedTreatmentLymphoma NOS / Neuroblastomas / Tumors, Central Nervous System / Wilms Tumor1
Not AvailableCompletedTreatmentLysosomal Storage Diseases / Peroxisomal Disorders1
Not AvailableNo Longer AvailableNot AvailableCutaneous Melanoma / Hepatic cancer metastatic / Ocular Melanoma1
Not AvailableRecruitingNot AvailableMetastatic Melanoma1
Not AvailableRecruitingTreatmentAdvanced Intra-Ocular Retinoblastoma / Retinoblastoma1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / CNS Tumors / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)1
Not AvailableRecruitingTreatmentBare Lymphocyte Syndrome / CD40 Ligand Deficiency / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Griscelli Syndrome / Hyper IgM Syndrome / Langerhan's Cell Histiocytosis / Lymphohistiocytosis, Hemophagocytic / Omenn's Syndrome / Reticular Dysgenesis / SCID / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
Not AvailableRecruitingTreatmentChronic Leukemias / Leukaemia, Acute / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentHaplo-Cord Transplantation1
Not AvailableRecruitingTreatmentLeukemias1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentMultiple Myeloma (MM)1
Not AvailableRecruitingTreatmentNeuroblastomas2
Not AvailableRecruitingTreatmentRetinoblastoma1
Not AvailableRecruitingTreatmentUnilateral Retinoblastoma1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma NOS1
Not AvailableWithdrawnTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I AIDS-related Lymphoma / Stage II AIDS-related Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableWithdrawnTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableWithdrawnTreatmentBasal Cell Carcinoma of the Skin / Eccrine Carcinoma of the Skin / Recurrent Adult Soft Tissue Sarcoma / Recurrent Melanoma / Recurrent Skin Cancer / Squamous Cell Carcinoma of the Skin / Stage III Adult Soft Tissue Sarcoma / Stage IIIB Melanoma / Stage IIIC Melanoma / Stage IV Adult Soft Tissue Sarcoma / Stage IV Melanoma1
PharmacodynamicsMelphalan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.
Mechanism of actionAlkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases (primarily at the N-7 position of guanine and to a lesser extent, at the N-3 position of adenine), forming monoadducts and resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
Related Articles
AbsorptionIncomplete, variable, 25-89% post oral dose
Volume of distribution
  • 0.5 L/kg
Protein bindingModerate to high (60 to 90%), primarily to albumin and, to a lesser extent, alpha 1-acid glycoprotein. 30% is irreversibly bound.
Metabolism

Melphalan is not actively metabolised, it spontaneously degrades to mono and dihydroxy products.

Route of eliminationThe 24-hour urinary excretion of parent drug in these patients was 10% ± 4.5%, suggesting that renal clearance is not a major route of elimination of parent drug.
Half life1.5 (±0.83) hours
ClearanceNot Available
ToxicityVomiting, ulceration of the mouth, diarrhea, and hemorrhage of the gastrointestinal tract; The principal toxic effect is bone marrow suppression. LD50=11.2 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
ALT-110The risk or severity of adverse effects can be increased when Melphalan is combined with ALT-110.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Melphalan.Investigational
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Melphalan.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Melphalan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Melphalan.Approved
CarmustineThe risk or severity of adverse effects can be increased when Melphalan is combined with Carmustine.Approved
CDX-110The risk or severity of adverse effects can be increased when Melphalan is combined with CDX-110.Investigational
ClozapineThe risk or severity of adverse effects can be increased when Melphalan is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Melphalan.Approved, Investigational
CyclosporineMelphalan may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Melphalan.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Melphalan.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Melphalan.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.Approved, Investigational
FingolimodMelphalan may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Melphalan is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Melphalan is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Melphalan is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Melphalan is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Melphalan is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Melphalan.Withdrawn
Nalidixic AcidThe risk or severity of adverse effects can be increased when Nalidixic Acid is combined with Melphalan.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Melphalan.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Melphalan.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melphalan.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Melphalan is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Melphalan.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Melphalan.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Melphalan.Approved
SRP 299The risk or severity of adverse effects can be increased when Melphalan is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Melphalan.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Melphalan is combined with TG4010.Investigational
TofacitinibMelphalan may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Melphalan.Approved, Investigational
Food Interactions
  • Take on an empty stomach. Food decreases bioavailabilty by approximately 30%. Increase liquid intake.
References
Synthesis Reference

DrugSyn.org

US3032584
General References
  1. Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N: Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 2008 Apr;21(4):787-95. doi: 10.1021/tx7004508. Epub 2008 Feb 14. [PubMed:18324787 ]
  2. Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP: Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15. [PubMed:16781199 ]
  3. Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993 Oct;68(4):732-7. [PubMed:8398701 ]
External Links
ATC CodesL01AA03
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (175 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9523
Blood Brain Barrier-0.6073
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.983
P-glycoprotein inhibitor IINon-inhibitor0.9192
Renal organic cation transporterNon-inhibitor0.811
CYP450 2C9 substrateNon-substrate0.8457
CYP450 2D6 substrateNon-substrate0.7432
CYP450 3A4 substrateNon-substrate0.7553
CYP450 1A2 substrateInhibitor0.779
CYP450 2C9 inhibitorNon-inhibitor0.9348
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9193
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9863
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.7873
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.9179 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8187
hERG inhibition (predictor II)Non-inhibitor0.8488
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit; liquid; powder, for solutionIntravenous
TabletOral2 mg
Tablet, film coatedOral2 mg/1
Injection, powder, lyophilized, for solutionIntravenous50 mg/10mL
Kit
KitIntravenous
Prices
Unit descriptionCostUnit
Alkeran 50 mg vial1971.72USD vial
Melphalan hcl 50 mg vial1845.6USD vial
Alkeran 2 mg tablet5.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341114 No2000-10-102017-10-10Canada
US8410077 No2009-03-132029-03-13Us
US9200088 No2009-03-132029-03-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point182.5 °CPhysProp
water solubility< 0.1 g/100 mL at 22 °CNot Available
logP-0.52SANGSTER,J (1994) @pH=7.4
Predicted Properties
PropertyValueSource
Water Solubility0.358 mg/mLALOGPS
logP-0.22ALOGPS
logP0.25ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)1.29ChemAxon
pKa (Strongest Basic)9.51ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area66.56 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity78.23 m3·mol-1ChemAxon
Polarizability31.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPhenylalanine and derivatives
Alternative Parents
Substituents
  • Phenylalanine or derivatives
  • 3-phenylpropanoic-acid
  • Alpha-amino acid
  • Amphetamine or derivatives
  • L-alpha-amino acid
  • Nitrogen mustard
  • Tertiary aliphatic/aromatic amine
  • Aniline or substituted anilines
  • Dialkylarylamine
  • Aralkylamine
  • Monocyclic benzene moiety
  • Benzenoid
  • Amino acid
  • Tertiary amine
  • Carboxylic acid
  • Monocarboxylic acid or derivatives
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Primary aliphatic amine
  • Primary amine
  • Carbonyl group
  • Organopnictogen compound
  • Alkyl halide
  • Amine
  • Organic oxygen compound
  • Alkyl chloride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Monahan SD, Subbotin VM, Budker VG, Slattum PM, Neal ZC, Herweijer H, Wolff JA: Rapidly reversible hydrophobization: an approach to high first-pass drug extraction. Chem Biol. 2007 Sep;14(9):1065-77. [PubMed:17884638 ]
  4. Lee PC, Kakadiya R, Su TL, Lee TC: Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia. 2010 May;12(5):376-87. [PubMed:20454509 ]
  5. Wang F, Li F, Ganguly M, Marky LA, Gold B, Egli M, Stone MP: A bridging water anchors the tethered 5-(3-aminopropyl)-2'-deoxyuridine amine in the DNA major groove proximate to the N+2 C.G base pair: implications for formation of interstrand 5'-GNC-3' cross-links by nitrogen mustards. Biochemistry. 2008 Jul 8;47(27):7147-57. doi: 10.1021/bi800375m. Epub 2008 Jun 13. [PubMed:18549246 ]
  6. Vasquez KM: Targeting and processing of site-specific DNA interstrand crosslinks. Environ Mol Mutagen. 2010 Jul;51(6):527-39. doi: 10.1002/em.20557. [PubMed:20196133 ]
  7. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP: Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica. 2007 Nov;92(11):1505-12. [PubMed:18024399 ]
  8. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS: The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005 Jul 15;106(2):698-705. Epub 2005 Mar 31. [PubMed:15802532 ]
  9. Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP: Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15. [PubMed:16781199 ]
  10. Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N: Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 2008 Apr;21(4):787-95. doi: 10.1021/tx7004508. Epub 2008 Feb 14. [PubMed:18324787 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peptide antigen binding
Specific Function:
Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Involved in cellular amino acid uptake. Acts as an amino acid exchanger. Involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the ...
Gene Name:
SLC7A5
Uniprot ID:
Q01650
Molecular Weight:
55009.62 Da
References
  1. Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993 Oct;68(4):732-7. [PubMed:8398701 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 21, 2017 03:17